p53 immunohistochemistry as a prognostic marker in bladder cancer -: Playground for urology scientists?
p53 immunohistochemistry as a prognostic marker in bladder cancer -: Playground for urology scientists?
复制标题
DOI：
10.1159/000020364
复制
发表时间：
2000-12-01
期刊：
影响因子：
23.4
通讯作者：
Fradet, Y
中科院分区：
文献类型：
--
作者：
Schmitz-Dräger, BJ;Goebell, PJ;Fradet, Y
目的：p53抑癌基因异常在多种不同类型的肿瘤中已有报道。此外，在尿路上皮癌中，P53蛋白的积聚与患者的不良预后有关。尽管发表的论文越来越多，但仍然存在困惑，因为关于膀胱癌中P53积累的关键问题仍然没有答案。这篇手稿的目的是回顾所有已发表的关于P53积聚与膀胱癌患者预后的关系的文献。方法：在通过Medline检索到的138篇文献中，有43篇试验符合3,764名患者的入选标准。结果：由于抗体的选择和不同分界值的使用、研究设计和患者选择等技术方面的原因，这些试验之间的比较产生了明显的差异。结论：从这一分析可以看出，进一步的回溯性研究显然无助于问题的解决，因此是过时的。显然需要标准化化验程序和对标本的评估，以及启动一项预期的多中心试验以提供明确的答案，版权所有(C)2000 S.Karger AG，巴塞尔。
Objectives: Anomalies of the p53 tumor suppressor gene have been reported for a variety of different tumor types. Also in urothelial cancer accumulation of the P53 protein has been linked with an unfavorable prognosis of the patients. Despite the growing number of publications confusion remains because key questions regarding p53 accumulation in bladder cancer are still unanswered. The objective of this manuscript was to review all published literature on the association of p53 accumulation and prognosis of patients with bladder cancer. Furthermore, putative reasons for the conflicting results should be defined as a basis for future research.Methods: The entry criteria for the analysis were met by 43 trials comprising 3,764 patients out of 138 publications found through Medline search.Results: Comparison between the trials yielded considerable differences obviously due to technical aspects, e.g. the selection of the antibody and the use of different cut-off values, study design and patient selection.Conclusions: From this analysis it becomes evident that further retrospective investigations will not contribute to the solution of the problem and thus are obsolete. There is an obvious need for standardization of the assay procedure and the assessment of the specimens as well as for the initiation of a prospective multicenter trial to provide definite answers, Copyright (C) 2000 S. Karger AG, Basel.